Increasing numbers of bacteria are becoming resistant to antibiotics, escalating the number of patients dying from untreatable infections. In particular, Gram-negative bacteria are a major cause for illness and death around the world.
Pept-ins present a promising and novel solution to antimicrobial resistance. While most APRs are unique, a small minority allows for redundancy in multiple proteins or across multiple pathogens. Aelin Therapeutics has designed Pept-ins to target such cross-reactive APRs in the bacterial proteome, leading to a selective proteostatic collapse of the bacteria with no toxicity to human host’s cells while inducing death (cidality) of the targeted bacteria. This clears even multi-drug resistant (MDR) infections quickly and efficiently.
Preclinical data of our antimicrobial Pept-ins demonstrate:
- 5 WHO criteria met: new mode of action, new chemistry, new targets, fast killing, no cross-resistance to other antibiotic classes
- Pept-ins kill bacteria rather than suppressing growth
- They have a broad activity spectrum, targeting multiple bacterial species with one Pept-in
- Activity is not influenced by the current MDR genotype or phenotype
- Resistance develops very slow, if at all, thanks to the fast kinetics of killing and its effect on multiple proteins creating a larger hurdle for corrective mutations
- Effectiveness against 150 WHO-listed pathogens and clinical isolates (including isolates with existing resistance to current treatments)